Unicycive Therapeutics Inc (NASDAQ:UNCY) has a beta value of 2.11 and has seen 0.38 million shares traded in the recent trading session. The company, currently
Unicycive Therapeutics Inc (NASDAQ:UNCY)’s traded shares stood at 0.48 million during the last session, with the company’s beta value hitting 2.13. At the close of
In the last trading session, 2.71 million Unicycive Therapeutics Inc (NASDAQ:UNCY) shares changed hands as the company’s beta touched 2.07. With the company’s per share
In the last trading session, 1.49 million Unicycive Therapeutics Inc (NASDAQ:UNCY) shares changed hands as the company’s beta touched 2.11. With the company’s per share
In last trading session, Unicycive Therapeutics Inc (NASDAQ:UNCY) saw 1.37 million shares changing hands with its beta currently measuring 2.14. Company’s recent per share price
Unicycive Therapeutics Inc (NASDAQ:UNCY) has a beta value of 2.15 and has seen 3.67 million shares traded in the last trading session. The company, currently
Unicycive Therapeutics Inc (NASDAQ:UNCY) has a beta value of 2.15 and has seen 2.02 million shares traded in the recent trading session. The company, currently
During the last session, Unicycive Therapeutics Inc (NASDAQ:UNCY)’s traded shares were 0.58 million, with the beta value of the company hitting 2.14. At the end
In the last trading session, 2.07 million shares of the Unicycive Therapeutics Inc (NASDAQ:UNCY) were traded, and its beta was 2.07. Most recently the company’s
In today’s recent session, 0.85 million shares of the Unicycive Therapeutics Inc (NASDAQ:UNCY) have been traded, and its beta is 2.07. Most recently the company’s
Marketing Sentinel delivers exclusive content, news, articles, and comprehensive coverage of events in the USA and worldwide with a commitment to reliability, objectivity, and timeliness.
© 2024, Powered by Smart TechOne
